Zimmer Biomet Holdings (ZBH) EBITDA (2009 - 2026)

Zimmer Biomet Holdings' EBITDA history runs 18 years deep, the most recent figure standing at $373.2 million for Q1 2026.

• In Q1 2026, EBITDA rose 27.68% year-over-year to $373.2 million; the TTM figure through Mar 2026 stood at $1.2 billion (down 10.14% YoY), while the FY2025 annual figure was $1.1 billion, down 14.59% from the prior year.
• EBITDA was $373.2 million for Q1 2026 at Zimmer Biomet Holdings, up from $154.5 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $389.0 million in Q4 2024 to a low of -$28.3 million in Q4 2022.
• Historically, EBITDA has averaged $278.3 million across 5 years, with a median of $292.3 million in 2025.
• Biggest YoY gain for EBITDA was 2775.36% in 2022; the steepest drop was 121.15% in 2022.
• A 5-year view of EBITDA shows it stood at -$28.3 million in 2022, then soared by 1351.59% to $354.2 million in 2023, then grew by 9.82% to $389.0 million in 2024, then sank by 60.28% to $154.5 million in 2025, then soared by 141.55% to $373.2 million in 2026.
• The last three EBITDA figures came in at $373.2 million (Q1 2026), $154.5 million (Q4 2025), and $351.3 million (Q3 2025), per Business Quant data.